DPYD is an important enzyme involved in pyrimidine base degradation and catabolism. DPYD catalyzes the reduction of uracil and thymine and also is a critical enzyme in the degradation of the chemotherapeutic drug 5-fluoruracil. DPYD is expressed in most cells and has highest activity in the liver and monocytes. Mutations in DPYD give rise to a range of symptoms and syndromes in patients ranging from no symptoms to highly convulsive and mental retardation caused by excessive amounts of uracil or thymine present in the blood. Because of its ability to degrade 5-fluorouracil, DPYD is studied as a cancer marker and a measure of therapeutic effects in many cancers. Recent research also shows that DPYD levels in the liver are regulated via microRNA interactions and an offer a new opportunity for modulation of this critical enzyme in health and disease.
免疫原
Epitope: Near N-terminus
KLH-conjugated linear peptide corresponding to human Dihydropyrimidine dehydrogenase/DPYD near the N-terminus.
應用
Research Category Apoptosis & Cancer
Research Sub Category Apoptosis - Additional
This Anti-Dihydropyrimidine dehydrogenase/DPYD Antibody is validated for use in Western Blotting and Immunohistochemistry for the detection of Dihydropyrimidine dehydrogenase/DPYD.
Western Blotting Analysis: 2.0 µg/mL from a representative lot detected Dihydropyrimidine dehydrogenase/DPYD in 10 µg of human liver tissue lysate. Immunohistochemistry Analysis: A 1:50 dilution from a representative lot detected Dihydropyrimidine dehydrogenase/DPYD in human liver tissue.
品質
Evaluated by Western Blotting in human small intestine tissue lysate.
Western Blotting Analysis: 2.0 µg/mL of this antibody detected Dihydropyrimidine dehydrogenase/DPYD in 10 µg of human small intestine tissue lysate.
標靶描述
~110 kDa observed. Uncharacterized band at ~47 kDa may be observed in some lysates.
外觀
Affinity purified
Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
儲存和穩定性
Stable for 1 year at 2-8°C from date of receipt.
其他說明
Concentration: Please refer to lot specific datasheet.
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
The predictive roles of dihydropyrimidine dehydrogenase (DPD) in patients who undergo curative resection and adjuvant chemotherapy with S-1, which is the oral 5-fluorouracil prodrug tegafur combined with oteracil and gimeracil, remain unclear. In the present study, the clinical data from
Frontiers in pharmacology, 13, 930470-930470 (2022-07-06)
Dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene, is the rate-limiting enzyme in 5-fluorouracil (5-FU) degradation. In Caucasians, four DPYD risk variants are recognized to be responsible for interindividual variations in the development of 5-FU toxicity. However, these risk variants